COVID-19 Funding Opportunities

1. National Institutes of Health (NIH)

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

Deadline: August 20, 2020; December 2, 2020; March 2, 2021

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.

Deadline: August 28, 2020 and December 1, 2020

Notice of Intent to Publish Funding Opportunity Announcements for the RADx-rad Initiative

The goal of RADx-rad is to support new, non-traditional approaches, including rapid detection devices and home-based testing technologies, that address current gaps in COVID-19 testing. The program will also support new or non-traditional applications of existing approaches to make them more usable, accessible, or accurate. This may include unconventional screening, biological or physiological markers, new platforms, and point-of-care devices, and data science and artificial intelligence technologies that address current gaps in COVID-19 testing. Despite the variety of activities included, the overall RADx-rad effort will be centrally aligned and coordinated to harmonize the data collection, storage, and management, providing an opportunity to further explore and identify additional approaches to understand this novel virus. Advances through RADx-rad may also be foundational to informing a more expedient research response to future emerging pathogens.

Deadline: September 2020

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Deadline: September 8, 2020
COVID-19 Funding Opportunities

Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

**Deadline: September 8, 2020**

National Heart, Lung, Blood Institute (NHLBI)

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19). NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

**Deadline: Rolling, through October 5, 2020**

National Institute of General Medical Sciences (NIGMS)

Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).

**Deadline: Rolling through February 6, 2021**

National Institute of Allergy and Infectious Diseases (NIAID)

NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Topics include: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

**Deadline: Rolling, through March 25, 2021**

National Institute of Drug Abuse (NIDA)

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus. NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

**Deadline: Rolling, through March 31, 2021**
National Institute of Allergy and Infectious Diseases (NIAID) - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
Deadline: April 30, 2021

II. National Science Foundation (NSF)
Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19
NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Topics include: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.
Deadline: Rolling, Project Pitch submission required

Dear Colleague Letter on the Coronavirus
The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge. For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.

Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)
The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

III. U.S. Department of Agriculture (USDA)
AFRI Education and Workforce Development: Innovating Formal and Non-Formal Educational Experiences in Food and Agricultural Sciences During the Time of Social Distancing
The COVID-19 pandemic is impacting the nation’s programs for youth development, education, and workforce development, including those in the food and agricultural sciences. Formal and non-formal education activities are in high demand as Americans continue social distancing to keep COVID-19 infection rates under control. The need for these programs is particularly prevalent in rural areas.
The Agriculture and Food Research Initiative (AFRI) Education and Workforce Development RFA now includes a new program area priority to address the need to develop and deploy rapid, reliable, and readily-adoptable strategies in workforce preparation through formal K-14 education, as well as in youth development through non-formal education to cultivate interest and competencies in STEM and agriculture. Funded projects are expected to develop tools, techniques, and other practices that can be rapidly adopted at home or by educators and extension specialists to ensure the effective education of K-14 students and other youth development opportunities.
Deadline: August 20, 2020
National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI)

In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines. Focus areas of interest include, but are not limited to the following: (1) Animal Nutrition, Growth and Lactation (A1231), (2) Critical Agricultural Research and Extension (CARE) (A1701), (3) Diseases of Agricultural Animals (A1221), (4) Food Safety and Defense (A1332), (5) Foundational Knowledge of Plant Products (A1103) (6) Economics, Markets, and Trade (A1641)

**Deadline: Varies by program**

IV. Other US Funding Agencies

**Biomedical Advanced Research and Development Authority (BARDA)**

BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat. BARDA, with a total budget of $512 Million, is seeking proposals for projects related to products to diagnose, prevent or treat novel coronavirus infections

**Deadline: Rolling, through 10/31/2020**

**Fast Grants**

Fast grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

**Due Date: Rolling, award decisions made in 48 hours**

**Ohio Department of Agriculture – Coronavirus Relief Fund: Local Fair Economic Support**

Ohio leaders recognize that county and independent fairs are so very important to the communities they serve and to the young people in 4-H and FFA, who have livestock, as well as non-livestock projects. Governor DeWine, Lt. Gov. Husted, House Speaker Householder, and Senate President Obhof have established that it is necessary to provide Coronavirus Relief Funding to County and Independent Fairs in Ohio to ensure that fairs are conducted in a safe manner, consistent with good health practices necessitated by COVID-19. The leaders of Ohio government have determined that the level of necessary funding is $50,000 for each fair that conducts a junior fair during calendar year 2020 and $15,000 for each fair that does not conduct a junior fair during calendar year 2020. This economic support is necessary to protect the health and safety of Ohioans due to the COVID-19 pandemic. In exchange for receiving a payment, each fair receiving Coronavirus Relief Funds agrees to conduct activities in accordance with public health requirements outlined by Exhibit A in the letter from the leaders to Fair Board members dated June 9, 2020. Additionally, please note that the Ohio Department of Health Director’s Order on June 16, 2020 Reopening County Fairs and Animal Exhibitions, with Exceptions, establishes requirements for social distancing, sanitization, and other sector-specific requirements that are necessary in order to contain the spread of COVID-19.

**Deadline: Not Specified**

**Wellcome, Bill & Melinda Gates Foundation, and Mastercard**

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The Accelerator is seeking partners for the following activities:

- Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
- Developing drugs or monoclonal antibodies that pass initial screening.
- Scaling up production and commercialization of successful drugs and monoclonal antibodies.

**Deadline: Not Specified**